SN//Connect

Practical Guidance on Mental Health and Physician Burnout

Latest News

Practical Steps for Physician Burnout

Therapy for physicians is important. Providers can be consumers of therapy, and there should be no shame in seeking help. Dr. Elizabeth Jewell says to identify risk factors. “Middle-aged women, and associate professors tend to be high risk [for mental health issues]. A lot of it has to do with busier clinical practices, job expectations, and responsibilities at home. As a society, we need to figure that out.”

Learn More

Should PARP Inhibitors Be Offered to All Women?

When it comes to PARP inhibitors, Dr. Rebecca Arend of the University of Alabama says, “The message is not that each patient should get a PARP inhibitor no matter what, but that it is an awareness that we need to put out into the community.”

Learn More

‘Exciting’ New Therapies, Including BTK Inhibitors and Monoclonal Antibodies, Promising for CLL

In recent years, the treatment of chronic lymphocytic leukemia (CLL) has undergone a seismic shift, with chemotherapy being replaced by a new and more effective generation of drugs. One of the "really exciting" therapies to emerge is the Bruton's tyrosine kinase inhibitors.

Learn More

Obinutuzumab Plus Venetoclax Produces Significant Survival Benefits in CLL

For decades, chemotherapy was the foundation of treatment for chronic lymphocytic leukemia (CLL). Today, monoclonal antibodies like obinutuzumab have become part of the standard of care for CLL patients.

Learn More

CAR T-Cell Therapy is a ‘Revolution in Cancer Immunotherapy’

Chimeric antigen receptor (CAR) T-cell therapy is "paradigm changing" -- a "revolution in cancer immunotherapy." This treatment has ushered in a new era of therapy for blood cancer patients.

Learn More

To Treat Ovarian Cancer With PARP Inhibitors or Not: Factoring the Progression-Free Survival Benefit and Side Effects Into the Decision

PARP inhibitors like niraparib (Zejula) are an effective tool against ovarian cancer. The NOVA trial established that niraparib as maintenance therapy in platinum-sensitive patients significantly improved progression-free survival compared to placebo, regardless of women's BRCA or homologous recombination deficiency (HRD) status. Then, the PRIMA study found the treatment extended PFS in patients with newly diagnosed ovarian cancer, with or without HRD deficiency.

Learn More

CAR T-Cell Therapy is ‘Exciting,’ But Also ‘Overwhelming’ for Patients

Chimeric antigen receptor (CAR) T-cell therapy has been transformative in blood cancer therapy, particularly for patients with previously poor outcomes; however, producing the CAR T cells can be a complex process.

Learn More

Patients Need Careful Monitoring for CAR T-Cell Therapy Side Effects

Chimeric antigen receptor (CAR) T-cell therapy has become a major ally in the treatment of certain lymphomas and leukemias. However, this therapy is not without risks.

Learn More